Shuttle Pharmaceuticals Holdings, Inc.
SHPHHealthcare|Drug Manufacturers - Specialty & Generic|US
$5.58
+0.55 (+10.81%)
Tangible Book / Share
$10.38
Cash / Share
$0.09
Financials
Financial Snapshot
Market Cap
$26.6M
Enterprise Value
$26.7M
Revenue (TTM)
$0.00
Net Income (TTM)
-$10.3M
Cash & Investments
$90.2K
Net Cash
-$104.9K
Free Cash Flow (TTM)
-$6.5M
Operating CF (TTM)
-$6.6M
Debt/Equity
0.01
Cash Runway & Burn Rate
Cash on Hand
$90.2K
Quarterly Burn
$1.6M
Monthly Burn
$548.7K
Est. Runway
~0.1 quarters
| Metric | Trend | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Investments | $50.7K | $352.4K | $117.2K | $504.7K | $8.4M | $5.5M | $1.9M | $334.0K | $90.2K | |
| Operating Cash Flow | -$202.7K | -$566.7K | -$26.8K | -$300.3K | -$2.7M | -$5.6M | -$7.3M | -$9.5M | -$6.6M | |
| Free Cash Flow | -$202.7K | -$566.7K | -$37.6K | -$300.3K | -$2.7M | -$5.6M | -$7.3M | -$9.5M | -$6.5M | |
| Capital Expenditure | $0.00 | $0.00 | -$10.8K | $0.00 | $0.00 | -$19.0K | $0.00 | $5.00 | $36.0K | |
| Financing Cash Flow | $160.6K | $868.4K | $70.1K | $687.9K | $10.6M | $2.6M | $3.8M | $11.0M | $10.4M |
R&D Spending
R&D (TTM)
$1.8M
R&D Intensity
—
R&D Growth vs Prior
-56.1%
| Metric | Trend | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| R&D Expense | -$836.00 | $55.6K | $161.8K | $1.0M | $1.0M | $3.5M | $3.6M | $4.1M | $1.8M | |
| SG&A | $186.0K | $513.1K | $347.8K | $721.2K | $1.3M | $2.4M | $4.1M | $7.9M | $6.7M |
Income Statement
| Metric | Trend | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Cost of Revenue | $18.7K | $18.0K | $55.0K | $60.8K | $6.0K | $0.00 | $0.00 | $0.00 | $922.4K | |
| Gross Profit | -$18.7K | -$18.0K | -$55.0K | -$60.8K | -$6.0K | $0.00 | $0.00 | $0.00 | -$922.4K | |
| R&D | -$836.00 | $55.6K | $161.8K | $1.0M | $1.0M | $3.5M | $3.6M | $4.1M | $1.8M | |
| SG&A | $186.0K | $513.1K | $347.8K | $721.2K | $1.3M | $2.4M | $4.1M | $7.9M | $6.7M | |
| Operating Income | -$203.9K | -$586.6K | -$509.5K | -$1.7M | -$2.3M | -$5.9M | -$7.7M | -$11.9M | -$11.2M | |
| Interest Expense | $10.9K | $30.9K | $39.6K | $50.8K | $670.6K | $2.6M | $1.4M | $70.8K | $49.3K | |
| Pretax Income | -$213.6K | -$626.1K | -$805.7K | -$1.2M | -$5.0M | -$6.6M | -$9.1M | -$11.7M | -$10.3M | |
| Net Income | -$213.6K | -$626.1K | -$805.7K | -$1.2M | -$5.0M | -$6.6M | -$9.1M | -$11.7M | -$10.3M | |
| EPS (Diluted) | -0.16 | -0.46 | -0.68 | -0.95 | -3.00 | -4.10 | -8857.30 | -71.60 | -30.80 | |
| EBITDA | -$184.0K | -$577.2K | -$711.2K | -$1.0M | -$4.3M | -$4.0M | -$7.8M | -$11.4M | -$9.5M | |
| Shares Out. (M) | 1.36 | 1.36 | 1.36 | 1.36 | 1.03 | 1.59 | 1.03 | 0.16 | 1.02 |
Balance Sheet
| Metric | Trend | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $50.7K | $352.4K | $117.2K | $504.7K | $8.4M | $2.6M | $1.9M | $334.0K | $90.2K | |
| Short-Term Investments | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $2.9M | $0.00 | $0.00 | $0.00 | |
| Total Current Assets | $102.5K | $614.0K | $341.2K | $509.6K | $8.6M | $5.6M | $2.2M | $502.9K | $396.4K | |
| Total Assets | $121.3K | $621.3K | $544.0K | $651.6K | $8.7M | $6.0M | $2.5M | $10.5M | $22.8M | |
| Total Current Liabilities | $405.6K | $593.8K | $2.1M | $2.2M | $975.7K | $1.0M | $1.5M | $8.0M | $3.5M | |
| Long-Term Debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $135.1K | $0.00 | $0.00 | $0.00 | |
| Total Liabilities | $405.6K | $593.8K | $2.2M | $2.3M | $975.7K | $1.9M | $1.8M | $8.2M | $3.6M | |
| Stockholders' Equity | -$284.3K | $27.5K | -$1.7M | -$1.6M | $7.7M | $4.1M | $709.2K | $2.3M | $19.2M | |
| Retained Earnings | -$1.3M | -$1.9M | -$4.5M | -$5.8M | -$8.9M | -$25.4M | -$34.6M | -$46.3M | -$51.6M |
Cash Flow Statement
| Metric | Trend | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$202.7K | -$566.7K | -$26.8K | -$300.3K | -$2.7M | -$5.6M | -$7.3M | -$9.5M | -$6.6M | |
| Capital Expenditure | $0.00 | $0.00 | -$10.8K | $0.00 | $0.00 | -$19.0K | $0.00 | $5.00 | $36.0K | |
| Free Cash Flow | -$202.7K | -$566.7K | -$37.6K | -$300.3K | -$2.7M | -$5.6M | -$7.3M | -$9.5M | -$6.5M | |
| Investing Cash Flow | $0.00 | $0.00 | -$10.8K | $0.00 | $0.00 | -$2.8M | $2.9M | -$3.1M | -$8.5M | |
| Financing Cash Flow | $160.6K | $868.4K | $70.1K | $687.9K | $10.6M | $2.6M | $3.8M | $11.0M | $10.4M | |
| Issuance of Stock | $100.00 | $912.5K | $0.00 | $0.00 | $10.0M | $0.00 | $4.0M | $11.2M | $10.5M | |
| Repurchase of Stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Net Debt Issuance | $160.5K | $205.9K | $70.1K | $687.9K | $600.7K | $3.2M | $133.5K | -$264.4K | -$61.1K | |
| Stock Based Comp. | $0.00 | $0.00 | $459.6K | $910.1K | $237.5K | $182.0K | $259.7K | $933.0K | $376.6K | |
| Net Change in Cash | -$42.1K | $301.7K | $32.4K | $387.6K | $7.9M | -$5.8M | -$656.3K | -$1.6M | -$4.7M |
Dilution Tracker
Shares Outstanding
5M
5-Year Share Growth
-87.9%
Stock Issuance (TTM)
$10.5M
| Metric | Trend | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| Shares Out. (M) | 1.36 | 1.36 | 1.36 | 1.36 | 1.03 | 1.59 | 1.03 | 0.16 | 1.02 | |
| Change vs Prior % | — | 0.0% | 0.0% | 0.0% | -23.8% | 53.7% | -35.1% | -84.1% | 519.8% | |
| Stock Issuance | $100.00 | $912.5K | $0.00 | $0.00 | $10.0M | $0.00 | $4.0M | $11.2M | $10.5M | |
| Stock Repurchase | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | |
| Stock Based Comp. | $0.00 | $0.00 | $459.6K | $910.1K | $237.5K | $182.0K | $259.7K | $933.0K | $376.6K |
Margins & Profitability
| Metric | Trend | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE % | 75.1% | -2280.5% | 47.7% | 70.8% | -65.1% | -162.6% | -1289.5% | -519.9% | -156.8% | |
| ROA % | -176.1% | -100.8% | -148.1% | -176.8% | -57.7% | -110.8% | -364.9% | -111.9% | -45.0% | |
| ROIC % | -679.0% | -137.2% | 62.4% | 268.5% | -27.8% | -106.0% | -403.4% | -460.8% | -57.8% |
Growth (Year over Year)
Fiscal years. Rising share count growth means dilution.
| Metric | Trend | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Gross Profit | 0.0% | 3.9% | 0.0% | -10.7% | 90.2% | 100.0% | 0.0% | 0.0% | |
| Operating Income | 0.0% | -187.7% | 0.0% | -242.1% | -34.5% | -151.4% | -30.6% | -54.8% | |
| Net Income | 0.0% | -193.1% | 0.0% | -43.0% | -333.6% | -32.0% | -38.7% | -28.2% | |
| EPS (Diluted) | 0.0% | -193.6% | 0.0% | -38.2% | -217.5% | -36.7% | -215931.7% | 99.2% | |
| Operating Cash Flow | 0.0% | -179.6% | 0.0% | -1019.4% | -787.8% | -109.3% | -31.3% | -29.4% | |
| Free Cash Flow | 0.0% | -179.6% | 0.0% | -697.7% | -787.8% | -110.0% | -30.8% | -29.4% | |
| R&D Expense | 0.0% | 6747.4% | 0.0% | 531.6% | 2.5% | 235.8% | 2.9% | 12.0% | |
| SG&A Expense | 0.0% | 175.9% | 0.0% | 107.4% | 78.9% | 84.1% | 71.7% | 92.8% | |
| Total Assets | 0.0% | 412.2% | 0.0% | 19.8% | 1228.0% | -31.2% | -57.9% | 318.0% | |
| Book Value / Share | 0.0% | 109.7% | 0.0% | 3.7% | 719.2% | -65.6% | -73.0% | 1903.0% | |
| Debt | 0.0% | 27.2% | 0.0% | 12.0% | -23.6% | 45.4% | 7.9% | -80.2% | |
| Diluted Shares | 0.0% | 0.0% | 0.0% | 0.0% | -23.8% | 53.7% | -35.1% | -84.1% |
Valuation
P/E (TTM)At Loss
P/S0.00
P/B0.30
10Y Low / Med / High1.31 / 356.98 / 3809318.18
EV/EBITDAAt Loss
EV/Revenue0.00
P/FCFAt Loss
Intrinsic Value Models (per share)
Tangible Book / Share
$10.38
Cash / Share
$0.09
| Metric | Trend | 2017 | 2018 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio | -490191.08 | -166941.43 | -112514.62 | -81439.15 | -1306.67 | -221.95 | -0.02 | -0.25 | -0.18 | |
| P/S Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| P/B Ratio | -367819.15 | 3809318.18 | -61875.93 | -64238.43 | 528.43 | 356.98 | 312.52 | 1.31 | 0.30 | |
| EV/EBITDA | -568507.56 | -181192.86 | -147070.59 | -100516.97 | -937.50 | -362.43 | -28.39 | -0.25 | -2.82 | |
| EV/Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Analyst Estimates & Quality
Altman Z-Score
-0.52
Distress
Piotroski F-Score
1
Weak